Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan

Master et al. (2021) declared that the unproven stem cell intervention (SCI) industry is a global health problem. We fully agree with this opinion but would like to point out that there are financial risks. In this letter, we estimate the total refund amount paid by the government for cell-based interventions offered under private practice in Japan.